9.4 OTC, Behind-the-Counter & Restricted Nonprescription Sales

The Legend/OTC Baseline Behind Every BTC Rule

Every restriction in this section sits on top of the same federal foundation: the Durham-Humphrey Amendment of 1951 (FDCA § 503(b)), which split drugs into legend (prescription) products — labeled "Rx only" and unsafe for unsupervised self-use — and OTC products generally recognized as safe and effective (GRAS/GRASE) for self-selection and self-administration with adequate labeling. A behind-the-counter (BTC) product, like pseudoephedrine, is legally an OTC drug — no prescription is required — but access is restricted to the point of sale (locked case, pharmacy staff release) rather than an open shelf. Keeping this three-tier structure straight (legend vs. OTC vs. BTC) prevents a common MPJE error: treating a BTC product as though it were legend, or a legend product as though counter placement alone could make it OTC.

No New York-Specific Pseudoephedrine Statute — A Federal-Only Rule

This is one of the most commonly mis-answered MPJE topics: New York has never enacted a state statute duplicating the federal Combat Methamphetamine Epidemic Act (CMEA). Bills to codify CMEA-style limits into New York's General Business Law were introduced repeatedly — for example, S.5036 (2011), S.627 (2015), S.1236 (2017), and A.6720 (2019) — but none were enacted. The General Business Law section number those bills would have occupied, § 391-oo, was later used for an unrelated law governing the retail sale of OTC diet pills and dietary supplements for weight loss or muscle building, not methamphetamine precursors. A pharmacist practicing in New York is bound by the federal CMEA framework alone for pseudoephedrine (PSE) and ephedrine sales:

Because there is no New York statute layered on top, an MPJE question describing a New York-specific PSE quantity threshold or a New York-only PSE logbook statute is testing a trap — the correct answer is that New York relies on the federal floor with no additional state law.

Dextromethorphan (DXM): A True New York-Specific Restriction

Unlike pseudoephedrine, dextromethorphan is independently restricted under New York law. General Business Law § 833 prohibits any retail establishment — not just pharmacies — from selling a product containing DXM as an active ingredient to a person under 18 without a valid prescription. Retailers must verify age unless the purchaser reasonably appears to be at least 25. Violations carry a civil penalty of $250 per violation. On the exam, remember that New York's DXM restriction is an age-based, point-of-retail-sale rule that applies broadly, not a pharmacy-only or behind-the-counter placement rule the way federal PSE restrictions are.

Naloxone: Statewide Standing Order Under PHL § 3309

New York authorizes non-patient-specific dispensing of naloxone under Public Health Law § 3309. Since a statewide standing order took effect August 15, 2022, any New York-licensed pharmacist (or supervised pharmacy intern) may dispense naloxone to a person requesting it, or to someone positioned to assist a person at risk of overdose, without a patient-specific prescription. § 3309 also provides that acquiring, possessing, or using an opioid antagonist under this authority does not constitute the unlawful practice of a profession. Separately, the FDA approved certain naloxone nasal spray products for fully OTC sale (no prescription or standing-order pathway needed at all) in 2023 — meaning some naloxone formulations are federally OTC while others remain accessible only through New York's non-patient-specific standing-order pathway. A pharmacist should know both routes exist and which applies to the specific product on the shelf.

Nonprescription Syringe Sales: PHL § 3381 (ESAP)

New York's Expanded Syringe Access Program (ESAP), codified at Public Health Law § 3381, allows pharmacies to sell hypodermic needles and syringes without a prescription to persons 18 years of age or older. Since a 2021 amendment (Chapter 433 of the Laws of 2021), pharmacies no longer need to register with the Department of Health to participate. Pharmacies selling under ESAP must keep syringes accessible only to pharmacy staff — not openly displayed for self-service — and must provide the required safety insert with each sale.

Putting the OTC/BTC Landscape Together

Common MPJE Traps

• Assuming New York has its own PSE quantity-limit or logbook statute — it does not; the federal CMEA is the sole controlling rule.
• Confusing GBL § 391-oo (diet pills/dietary supplements) with a meth-precursor law — the section number was reused after the earlier precursor bills failed to pass.
• Treating naloxone as requiring a patient-specific prescription in New York — the statewide standing order under PHL § 3309 removes that requirement.
• Forgetting the 18-and-older threshold for nonprescription syringe sales under ESAP.